Related by context. All words. (Click for frequent words.) 70 QRS width 65 Physical Function 64 aspartate aminotransferase AST 64 creatinine clearance 64 Unfractionated Heparin 64 QRS duration 64 baseline serum creatinine 64 x ULN 64 Non Responders 64 fraction LVEF 63 ischemia driven 63 TAXUS p value 63 mild renal insufficiency 63 mL/min/#.# m 2 63 Levels Linked 63 moderate hepatic impairment 63 Left Ventricular 63 periprocedural 63 left ventricular systolic 62 QTcF 62 % Confidence Interval 62 morphometric vertebral fractures 62 moderate renal impairment 62 CK MB 62 MACCE 62 Free Survival PFS 62 8mg/kg 62 log# IU mL 62 Mg Usa 62 Persistent Sleep 62 LVEF 62 4mg/kg 62 Statistically Significant 62 Primary endpoints 61 Alzheimer Disease Assessment 61 Pain Intensity 61 Peginterferon Alfa 2a 61 Predict Risk 61 repeat paracentesis 61 Montgomery Asberg Depression 61 Acetate Rectal Suppositories 61 Intraocular Pressure 61 Improves Survival 61 creatine kinase MB 61 Index CDAI 61 Cholinesterase Inhibitors 61 lopinavir r arm 61 Heat Dissipation 61 Improves Outcomes 61 IIIa inhibitor 61 lispro 61 g trans fats 61 severe neutropenia 61 Cardiac Troponin 61 ejection fractions 61 myocardial infarction ventricular fibrillation 61 Hamilton Anxiety Scale 61 Fracture Risk 61 Demonstrated Significant 61 Inhaled Corticosteroids 61 austriamicrosystems Introduces 61 Patients Receiving 61 plus GP IIb 61 Inventory BPI 61 budesonide pMDI 61 Ejection Fraction 60 oral antidiabetic medication 60 infliximab monotherapy 60 hemodynamically significant 60 Tasigna prolongs 60 Thrombolysis 60 -#.# log# copies mL 60 Mg Uk 60 calculated creatinine clearance 60 DAS# scores 60 nadolol 60 Hypertrophy 60 mcg QD 60 Kidney Function 60 Cardiovascular Events 60 mL kg 60 benazepril 60 QTc 60 -#.# ± [001] 60 stage IIIb IV 60 PROCTOCORT ® Suppository Hydrocortisone 60 REYATAZ r arm 60 Fasting blood glucose 60 tissue oxygen saturation 60 abacavir lamivudine 60 generalized edema 60 Chronic HCV 60 serum phosphorous 60 PCWP 60 PLX STROKE targeting 60 #.#mg/dL 60 certolizumab 60 -#.# mg dL [002] 60 log# copies mL 60 R# #mg BID 60 Median PFS 60 Viral Load 60 nonfatal myocardial infarction 59 adjunctive placebo 59 activated partial thromboplastin 59 atrial pacing 59 unfractionated heparin UFH 59 Prognostic significance 59 Sustained virologic response 59 estimated glomerular filtration 59 Carotid Artery Stenting 59 prednisone prednisolone plus 59 aspartate aminotransferase 59 β blocker 59 Hormone Refractory Prostate Cancer 59 sUA 59 Fibromyalgia Impact Questionnaire 59 Prolongs Survival 59 Critically Ill Patients 59 IELT 59 NYHA Class III 59 Waist Circumference 59 alanine aminotransferase 59 Long Term Outcomes 59 CrCl 59 AUC0 59 #.#/#.# mmHg [001] 59 lowest tertile 59 Operative mortality 59 lispro alone 59 Rating Scale MADRS 59 BENICAR HCT 59 Carotid Stenting 59 Orthostatic Hypotension 59 apnea hypopnea index 59 baseline HbA1c 59 NPH insulin 59 phonophobia 59 nausea photophobia 59 pyrexia mucositis sepsis febrile 59 Suppository Hydrocortisone Acetate Rectal 59 creatinine ratio 59 EURIDIS 59 q#h 59 dimensional echocardiography 59 HOMA IR 59 glomerular filtration rate 59 WIDTH 59 g dietary fiber 59 intima media thickness 59 mL/min/#.# m2 59 Less Invasive 59 Glycemic Control 59 oxycodone IR 59 #.#m #.#m #.#m [003] 59 transthoracic 59 mcg BID 59 QTc intervals 59 Hazard Ratio HR 59 aplastic anemia AA 59 Noise Ratio 59 plus methotrexate 59 SGOT 59 SGPT 59 confirmed CCyR 59 tirofiban 59 carotid artery intima media 59 severe renal impairment 59 receiving INTRON 59 #mg BID [001] 59 mg qd 59 Randomized Trials 59 FOLFOX4 alone 59 excess blasts RAEB 59 Relapsed Refractory 58 ALT elevation 58 XIENCE V vs. 58 Zometa hazard 58 refractory ischemia 58 HDL Cholesterol 58 somatostatin analog 58 6MWD 58 fasting plasma glucose FPG 58 inhaled budesonide 58 Main Outcome Measures 58 alfa 2a 58 Nat Clin Pract 58 Phospholipase 58 ps :# 58 #mmHg [001] 58 Appears Safe 58 lumbar spine BMD 58 plus dexamethasone 58 mediated dilation 58 crossclamp 58 3mg/kg 58 Montgomery Åsberg Depression 58 #Gy 58 Endothelial Function 58 Folfox 58 urinary albumin 58 Inhaled Nitric Oxide 58 lumbar spine bone 58 serum phosphate 58 Severity MSCS score 58 XIENCE V PROMUS Stent 58 Hyperlipidemia 58 Health Assessment Questionnaire 58 #mm Hg 58 Significantly Reduced 58 μmol L 58 intima media thickness IMT 58 neutrophil counts 58 Primary Endpoint 58 Lowers Risk 58 Bone Mineral Density 58 baseline FEV 58 J Am Coll 58 HOLE NO 58 NYHA Class II 58 Cognitive Impairment 58 hydroxymethyl coenzyme 58 mg QD 58 mU liter 58 elevated transaminases 58 left ventricular dysfunction 58 coronary stenosis 58 J Am Soc 58 dosed intravenously 58 unstable angina pectoris 58 ventricular dilation 58 glycosylated hemoglobin HbA1c 58 reintervention 58 atorvastatin #mg 58 mso footer margin 58 echocardiographic parameters 58 Myoglobin 58 thyroglobulin 58 Breast Density 58 WOMAC pain 58 Depressive Symptoms 58 Quiescent current 58 postintervention 58 subtrochanteric 58 ipsilateral stroke 58 dapagliflozin plus 58 hypertrichosis occurred 58 P = .# 58 Visual Analogue Scale VAS 58 Predict Dementia 58 Main Outcome Measure 58 ° sec 58 Pharmacokinetic parameters 58 pg mL 58 cTnI 58 ULORIC 58 Functional Outcomes 58 leucopenia 58 saline placebo 58 CCyR 58 REMICADE monotherapy 58 mL min 58 undergoing coronary artery 58 QT intervals 58 PREZISTA r arm 58 Systolic Blood Pressure 58 ¾ î 58 Skin sterol 58 adjunctive ABILIFY 58 Advanced Ovarian Cancer 58 nicardipine 58 Radiation Dose 58 ng dL 58 pulmonary artery pressure 58 administering XIFAXAN 58 sinus tachycardia 58 Bone Marrow Cells 58 #.#-#.# [011] 58 candesartan cilexetil 58 left ventricular diastolic 58 reinfarction 58 hypophosphatemia 58 PSA nadir 58 Non Inferiority 58 lactate dehydrogenase LDH 58 triiodothyronine 58 J Antimicrob Chemother 58 urine albumin 58 preintervention 58 serum aminotransferase levels 58 lipoprotein Lp 58 IIIa inhibitors 58 nondiabetic patients 57 preserved systolic 57 Diastolic 57 Brain Metastases 57 Blood Glucose 57 0 document.write sline 57 metastatic GIST 57 platelet inhibition 57 Prognostic Value 57 -#.# mg dL [001] 57 plus prednisone 57 C Reactive Protein 57 Cilostazol 57 mg m² 57 Stent Placement 57 anemia hemoglobin 57 Statistical Significance 57 mcg mL 57 Secondary endpoints included 57 Reduces Risk 57 Poorly Controlled 57 BYSTOLIC 57 troponin T 57 events MACE 57 bronchial hyperresponsiveness 57 Blood Clot Risk 57 Autologous Stem Cell Transplantation 57 Blood Cholesterol 57 OGTT 57 ACTEMRA TM 57 sUA levels 57 Cream USP 1 57 Statin Therapy 57 Lowering Blood Pressure 57 alanine aminotransferase ALT 57 response CCyR 57 Reduces Pain 57 See CLINICAL PHARMACOLOGY 57 diastolic BP 57 Lower Limb 57 g carbo 57 mH 57 Lipid Levels 57 2dB 57 mCi kg 57 malignancy HCM 57 Severe Asthma 57 ADCS CGIC 57 Echocardiographic 57 À º 57 Partial Onset Seizures 57 deep venous thromboses 57 intact parathyroid hormone 57 endometrial thickness 57 #.#.i#.rpm 57 #mg/dl 57 Rheumatoid Arthritis Patients 57 biochemical relapse 57 Colorectal Cancer Risk 57 CI #.#-#.# [001] 57 nmol liter 57 Survival Benefit 57 corrected QT interval 57 fractional shortening 57 atrioventricular block 57 x #mm WDH [002] 57 Vitamin D Linked 57 achieved CCyR 57 % CI #.#-#.# [003] 57 foveal thickness 57 -#.# ± [002] 57 THENCE SOUTH 57 irregular quivering 57 mcg kg 57 daily Infergen 57 NIHSS score 57 Expanded Disability Status 57 Nephrol Dial Transplant 57 NNT = 57 Blood Pressure Drugs 57 % CI #.#-#.# [007] 57 MADRS score 57 oxycodone CR 57 Cholesterol Levels 57 hepatic enzymes 57 hemoglobin Hb 57 serum triglycerides 57 β blockers 57 urinary cortisol 57 Available Seat Kilometres ASKs 57 Proc Am Soc 57 typ. 57 irbesartan 57 nonfatal MI 57 statin monotherapy 57 AuEq g t 57 pulmonary capillary wedge 57 hyperphenylalaninemia HPA due 57 Bone Metastases 57 Cause Mortality 57 triglyceride TG 57 cytopenias 57 dalteparin 57 Age Suitability 57 #mmHg [002] 57 Abdominal Fat 57 serum IGF 57 plasma HCV RNA 57 myocardial infarction stroke 57 PEG IFN 57 IU ml 57 Mortality Risk 57 prespecified secondary 57 receiving PEGINTRON 57 receiving prophylactic anticoagulation 57 transcranial Doppler ultrasound 57 #mg/day [002] 57 Active Ulcerative Colitis 57 colorectal adenoma 57 primary percutaneous coronary 57 achieved ACR# 57 Artery Disease 57 arterial thromboembolic events 57 Breast Cancer Recurrence 57 bFGF 57 PaO 2 57 3rd edn 57 mg TID 57 Combination Clinical Trial 57 Postoperative 57 #mg q8h 57 Brief Pain 57 ug dose 57 ventricular dilatation 57 nodular partial response 57 serum testosterone 57 ATACAND 57 nonfasting triglyceride levels 57 progression TTP 57 χ 56 mmol l 56 + #.#dB 56 Atherosclerotic 56 pmol L 56 ‰ ¥ 56 Cardiorespiratory fitness 56 NovoLog ® Mix 56 angioplasty stenting 56 - -winger Colby Armstrong 56 Core Length 56 cerebral oxygenation 56 #.#Hz 56 salmeterol fluticasone 56 Transient Response 56 Gene Variants 56 0mg 56 Gene Variant 56 GOVERNMENT MEETINGS 56 angiotensin II receptor blockers 56 r2 = 56 transaminases 56 0 g saturated 56 Scale EDSS 56 DAS# remission 56 mild renal impairment 56 Contrast Ratio 56 = null & 56 Relapsing Remitting Multiple Sclerosis 56 Eur J Endocrinol 56 Improved Survival 56 creatine kinase CK 56 Healthbeat Report 56 Hb A1C 56 #mg/kg [002] 56 serum creatinine levels 56 Sleep Disturbances 56 brand ciclesonide HFA 56 serum urate 56 % AST SGOT 56 peak VO2 56 mL sec 56 intravenous REOLYSIN 56 postoperative complication 56 dose atorvastatin 56 PASI scores 56 baseline Hb 56 Negative Syndrome 56 HBeAg seroconversion 56 Crohn Disease Activity 56 Discontinuous 56 glulisine 56 Unified Parkinson Disease 56 intraobserver 56 Signal Generator 56 + - Vulnerable 56 mg BID dose 56 left ventricular ejection 56 highest tertile 56 % CI #.#-#.# [005] 56 Systolic 56 annualized relapse 56 symptomatic VTE 56 aminotransferase ALT 56 MIC# [001] 56 Dose Response 56 fluticasone salmeterol 56 CRp 56 -#.# mmHg 56 Transesophageal 56 median PFS 56 paclitaxel eluting stents 56 normal ULN 56 x #mm WDH [001] 56 Claudication 56 methotrexate monotherapy 56 Androgen Deprivation 56 Scale cognitive subscale 56 Prostate Biopsy 56 melphalan prednisone 56 bioavailable testosterone 56 mU L 56 NIHSS 56 Eur Arch 56 intraclass correlation coefficient 56 binary restenosis 56 serum prostate 56 elevated ALT 56 Calcium Supplements 56 Â ± 56 expiratory flow 56 RECIST Response Evaluation Criteria 56 neurologic progression 56 preoperatively 56 bortezomib refractory 56 digit DMM 56 triglycerides TG 56 Data Suggest 56 serum sodium 56 Papillary 56 Cardiopulmonary bypass 56 Renal Function 56 LDL Cholesterol 56 Lung Cancer Risk 56 coronary revascularization 56 diastolic blood pressures 56 nonfatal stroke 56 Nephrol 56 chemoradiation therapy 56 CI -#.# 56 angiotensin converting enzyme inhibitor 56 Solid Tumors criteria 56 angiotensin converting enzyme 56 plasminogen activator inhibitor 56 #mg #mg #mg [003] 56 Taxus Stent 56 NYHA class 56 serum electrolytes 56 bivalirudin monotherapy 56 WEEK ENDING INDEX 56 Psoriasis Area 56 Testosterone Levels 56 HbA1c levels 56 LVSD 56 uM 56 prolactin levels 56 Soyabean Ext Bulk 56 Antidepressants Linked 56 bone marrow reticulin deposition 56 ACR# response 56 postdose 56 trough FEV1 56 ventricular ejection fraction 56 reduce serum phosphate 56 Genetic Defect 56 Hazard Ratio 56 aminotransferase levels 56 fasting triglyceride levels 56 AST ALT 56 Obese Patients 56 Kaplan Meier analysis 56 Orthop Surg 56 Beta Blockers 56 plus MTX 56 umol L 56 comparator arm 56 Ovarian Cancer Risk 56 urate lowering therapy 56 Antigen Specific 56 Score IPSS 56 Nazareth . 56 Anticancer Activity 56 cerebrovascular events 56 #mg QD [002] 56 rizatriptan 56 Cardiovascular Outcomes 56 secondary efficacy endpoint 56 hsCRP levels 56 Correlation Between 56 plus OBT 56 NYHA functional class 56 coronary artery stenosis 56 highly emetogenic 56 percutaneous transluminal coronary angioplasty 56 Shows Promise Against 56 #R #R #R [002] 56 acarbose 56 Retreatment 56 normothermic 56 Exposure Linked 56 CR nPR 56 #.#mmHg 56 #.#/#.# mm Hg [003] 56 laboratory abnormalities 56 & BOVESPA RSID3 56 Hypotension 56 Lung Function 56 Showed Significant 56 elevated lipase 56 #mg/dL [002] 56 Dementia Risk 56 Ambulatory Blood Pressure 56 argc 56 mg tid 56 cerebral perfusion 56 corticosteroid dose 56 Secondary Hyperparathyroidism 56 left ventricular LV 56 systemic embolism 56 graft occlusion 56 % CuEQ 56 recurrent ischemia 56 Secondary Endpoints 56 Genetic Variants 56 urinary N telopeptide 56 -#.# log# 56 cardiovascular hospitalizations 56 R LAV 56 Homes Sold tbr 56 permanently discontinue Vectibix 56 placebo PBO 56 diameter stenosis 56 mIU ml 56 CIBIC plus 56 plus glycoprotein IIb 56 pg ml 56 Obesity Linked 56 Recorded Sold As 56 Vitamin D Levels 56 ventricular tachycardia VT 56 Cognitive Problems 55 aortic crossclamp 55 Highly Accurate 55 μg liter 55 doxorubicin cyclophosphamide 55 Peg IFN 55 metformin sulfonylurea 55 mIU L 55 kg -1 55 cTnT 55 Equiv 55 Rating Scale UPDRS 55 transaminase elevations 55 plus medroxyprogesterone acetate 55 TLUS 55 Am J Cardiol 55 primary hypercholesterolemia 55 colesevelam HCl 55 prospectively stratified 55 Provides Unprecedented 55 Nebulized 55 len = 55 albumin excretion rate 55 desvenlafaxine succinate 55 serum magnesium 55 selective cerebral perfusion 55 Pediatric Patients 55 subscores 55 #mg BID [003] 55 Calcium Intake 55 HMG CoA reductase inhibitor 55 Symptom Improvement 55 Organ Rejection 55 exhaled NO 55 Impedance 55 ventricular dyssynchrony 55 subscore 55 mg hydrochlorothiazide 55 residual platelet reactivity 55 aldosterone antagonists 55 mg/m2/day 55 ps rms 55 Chemotherapy Improves 55 Q2W 55 placebo p = 55 kg m² 55 ABC/3TC 55 Anti Tumor Activity 55 μg kg 55 preoperative PSA 55 Asymptomatic 55 Patient Outcomes 55 carotid intima media 55 transferrin saturation 55 Cystatin C 55 ug ml 55 Naive Patients 55 hip BMD 55 non splenectomized 55 Immune Responses 55 underwent resection 55 SpO2 55 serum phosphorus 55 ACE Inhibitor 55 carotid stenosis 55 mcg kg REBETOL 55 serum potassium 55 microg 55 fasting triglycerides 55 hs CRP 55 NR CC 55 Significant Reductions 55 mg q#h 55 FOLFOX6 55 + PH# 55 Child Adolesc Psychiatry 55 Induces 55 reintubation 55 TNF Tumor Necrosis Factor 55 serum uric acid 55 leukocyte count 55 interquartile range 55 Erythropoietic therapies may 55 #.#ng/ml 55 Platform openSUSE 55 PSADT 55 fractional anisotropy 55 Type IIa 55 Ann Oncol 55 Strongly Linked 55 quetiapine risperidone 55 tolterodine ER 55 ARB telmisartan 55 metabolic alkalosis 55 Cognitive Function 55 CNS LS 55 Coronary Arteries 55 Moderate Drinking 55 Watchful Waiting 55 SINAD 55 Stroke Risk 55 mean ± SEM 55 1g fiber 55 glycated hemoglobin levels 55 Preterm Delivery 55 Sleep Patterns 55 LANTUS R 55 dehydroepiandrosterone sulfate 55 Impair 55 Who Underwent 55 ± SD 55 S# T# R# 55 #.#mg/kg [002] 55 mg/# hours 55 male Sprague Dawley 55 radical nephrectomy 55 Ventricular Tachycardia 55 mm Hg diastolic 55 Hazard Ratio = 55 BENICAR 55 isoenzyme 55 Bronchopulmonary Dysplasia 55 Phase Ib Clinical Trial 55 Secondary endpoints include 55 CIMZIA R 55 neuropathy sensory 55 Study Shows Benefits 55 Prostate Cancer Patients 55 Cholesterol Linked 55 Repeatability 55 Ozone Levels 55 tryptophan hydroxylase 55 Brain Aneurysms 55 Melbourne measured #kbps 55 aspirin clopidogrel 55 CIMZIA TM 55 Ishak fibrosis score 55 % CI #.#-#.# [004] 55 Index CDAI score 55 Gene Mutations 55 Diodes Incorporated Announces 55 serum leptin 55 systolic hypertension 55 GnRH agonist 55 hemodynamic parameters 55 aminotransferases 55 thromboembolic complications 55 Score TOS 55 Inflammatory Markers 55 ACE inhibitor ramipril 55 proximal DVT 55 ml min 55 pCR 55 Sexual Satisfaction 55 Follicular Lymphoma 55 PRADAXA #mg 55 XIENCE V demonstrated 55 Gene Mutation 55 postprocedure 55 ventricular tachyarrhythmias 55 Improves Accuracy 55 adefovir treated 55 severe NCI CTC 55 confidence intervals CIs 55 Median progression 55 Significant Reduction 55 ® fluocinonide Cream 55 paroxysmal AF 55 apolipoprotein B 55 deoxy 55 odds ratios ORs 55 liver histology 55 Carotid Artery Disease 55 pulmonary arterial 55 #.# Kenyan Shilling 55 #μg [001] 55 Univariate 55 TIMP 1 55 #mg/dL [001] 55 hematological parameters 55 Retention Rates 55 Hemoglobin Levels 55 -India Kanishka bombing 55 mucosal healing 55 ¸ ° 55 somnolence headache 55 Scale EDSS score 55 oral allopurinol 55 artery occlusion 55 #.# MHz [002] 55 pericardial effusion 55 interleukin IL -6 55 #.#mmol L [001] 55 % CI #.#-#.# [001] 55 Blood Glucose Levels 55 Pearson correlation coefficient 55 ± #.#mm [001] 55 Advanced Renal Cell 55 dactylitis 55 nontraumatic 55 leukopenia 55 nonischemic 55 Novel Method 55 oral levofloxacin 55 Prostate Cancer Risk 55 Spinal Fractures 55 TAXUS Express Stent 55 aminotransferase elevations greater 55 HAQ DI 55 insulin detemir 55 Smoking Linked 55 COPD Exacerbations 55 serum calcium 55 infarct size 55 + Pd g t 55 intraventricular 55 Brief Psychiatric 55 Remain Above 55 True Width 54 hemoglobin A1c levels 54 serum estradiol 54 Lnk 54 mCi 54 dacarbazine 54 EDSS scores 54 Helps Relieve 54 serum transaminases 54 weekly subcutaneous injections 54 Response Evaluation Criteria 54 linaclotide treated 54 cerebrovascular accident 54 CIMZIA TM certolizumab pegol 54 elevated creatinine 54 serum CRP 54 monocyte chemotactic protein 54 Ultrasensitive 54 oral rivaroxaban 54 maximal treadmill 54 discontinuations due 54 artery stenosis 54 low dose cytarabine 54 dexamethasone Decadron 54 Stent thrombosis 54 plasma leptin 54 FOLFIRI 54 conjunctival hyperemia 54 RLAI 54 QRS interval 54 #OHD 54 quetiapine XR 54 sinus rhythm 54 ritonavir boosted 54 Impairs 54 Kaplan Meier estimates 54 composite endpoint 54 LV dysfunction 54 - -Books Market Segmentation 54 biventricular repair 54 Prostate Cancer Recurrence 54 gram dietary fiber 54 improves glycemic 54 Lung Cancer Survival 54 interferon alfa 2b 54 intratumoral 54 mg ustekinumab 54 n Cooling Degree 54 interobserver 54 DAS# [002] 54 Laryngeal Cancer 54 Intensive blood glucose 54 microvolts 54 cisplatin vinorelbine 54 asymptomatic carotid stenosis 54 International Normalized Ratio 54 prolonged QT interval 54 microcirculatory improvement helping 54 Training Effectiveness 54 natriuresis 54 metformin monotherapy 54 Virologic Response 54 Serum creatinine 54 renal insufficiency 54 serum calcium levels 54 hemoglobin A1c HbA1c 54 erythrocyte sedimentation rate 54 achieved statistical significance 54 Glucose Levels 54 Intraocular pressure 54 intravenous bolus 54 symptomatic intracranial hemorrhage 54 mg simvastatin 54 K ras mutations 54 flutamide 54 TEAEs 54 ribavirin RBV 54 serum concentrations 54 QTc prolongation 54 Leukemias 54 patrick.graham @ thomson.com 54 g cm 54 HT 1A 54 urinary calcium 54 Aggressive Prostate Cancer 54 severe exacerbations 54 mEq L 54 simvastatin #mg 54 relapsed MM 54 Atypical Hemolytic Uremic Syndrome 54 Doppler sonography 54 Diamyd Medical Diamyd 54 abdominal distention 54 salmeterol fluticasone propionate 54 J Child Adolesc 54 Sydney measured #kbps 54 Bit Rate 54 transdermal estradiol 54 Test Detects 54 Fasting plasma glucose 54 pT3 54 nonfatal myocardial infarction MI 54 Apgar scores 54 Low Density Lipoprotein 54 echocardiographic 54 â ‰ ¥ 54 cytogenetic response 54 GORE TAG Device 54 FOREX Ringgit Closes 54 g t PGE 54 gadolinium enhancing lesions 54 noncardiac 54 IFN α 54 Surgical Procedures 54 κ 54 postoperative chemotherapy 54 total cholesterol triglycerides 54 mean baseline HbA1c 54 extracorporeal shock wave 54 lymphopenia 54 % Cu Eq 54 HDRS 54 Antipsychotic Drugs 54 LV ejection fraction 54 clodronate 54 R LANV CC 54 Finger Length 54 Severity Index PASI 54 serum LDL cholesterol 54 J Pediatr 54 Creatinine 54 Mortgage Rates Hit 54 Cmax 54 advanced adenoma 54 Gene Linked 54 glycosylated hemoglobin levels 54 Optical Zoom 54 dysuria 54 IPSS 54 radiotherapy RT